Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

- PMLiVE

Sanofi backs SMS chemotherapy compliance programme

Prost8Care delivers timed text message encouragement to cancer patients

- PMLiVE

Sanofi launches voice-guided epinephrine auto-injector in US

Auvi-Q extends pharma company's interests in innovative devices

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

AbbVie expects Humira to drive growth in inaugural guidance

First statement since split from Abbott

- PMLiVE

EC to investigate Novartis and J&J in antitrust probe

Claims companies agreed to delay entry of generic painkiller

Sanofi reception

US approval for Sanofi’s Kynamro in genetic cholesterol disorder

Comes one month after drug was turned down in Europe due to safety concerns

Novartis building

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension

- PMLiVE

NICE backs two cystic fibrosis treatments for NHS use

Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price

Bristol-Myers Squibb (BMS) building

BMS Q4 results see earnings increase despite fall in sales

Cost-cutting measures at pharma company help overcome patent losses

- PMLiVE

Amgen profits down on rising costs

R&D and general operating expenses cancel out rise in product sales

Novartis building

Novartis expects tough 2013 before a return to growth

Says it will take a year for new medicine sales to overcome Diovan patent loss

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links